All right. Good day, everybody. Welcome to UBS Biopharma Conference in London. Next company with me here, Alvotech. My name is Ash Verma. I cover specialty biotech and spec pharma, and we have Róbert and Balaji from Alvotech. Guys, thank you so much for joining us today.
Yeah, thank you, Ash. Pleasure.
Yeah, so a lot of exciting things going on with Alvotech. Maybe, I think most people are kind of familiar with the story, but if you can just kind of remind, what's the pure play biosimilar and-
Yeah
talk about some of the programs.
Yeah, exactly. I founded the company 2013. We knew that biologic would be the future of pharmaceutical, if you will. Those medications, as we all know, are quite effective, but very expensive. We predicted that there would be a very strong need for a company like ours post 2020. The concept was always pure play biosimilar, having end-to-end R&D, end-to-end manufacturing from vial fill to finished product, both drug substance, fill-finish, sterile. Then we do even assembly of our auto-injector. Then we have built out the commercial network now with 20 different partners, including Teva in U.S. and Advanz and STADA in Europe.
We have invested now over $2 billion into building the infrastructure, and we are super proud because we believe that we have one of the largest pipeline, in-house developed pipeline in the industry, and the company is clearly at a big inflection point today.
Right. Awesome. Maybe just, I guess there's a lot of focus on the base business, I'll start there, and then the exciting pipeline program coming for you. If you can kind of remind us, like the third quarter, how the business performance was, like there was STELARA, where is HUMIRA in terms of the opportunity?
Yeah. We did have a pretty decent quarter, third quarter. We delivered $31 million EBITDA and north of $110 million top line for the quarter. We are expecting absolutely record quarter in the fourth quarter. A lot of what we have been doing since middle of the year is basically been stockpiling for the fourth quarter, which will be, again, exceptionally month of December, for instance. If you look at what is on the market now, biosimilar to HUMIRA is doing very well in U.S. We have Teva as our partner, which is, of course, excellent partner, knows how to convert brands to biosimilars. They understand all the channel. Our product today is having second-best market share in the market.
We are seeing, of course, more conversion from HUMIRA to biosimilars, and I believe end of second quarter, that conversion was like a bit north of 60% and continues. We believe that Teva will continue to gain share. We launched into Europe into a bit more mature market because we decided to go for the high dose. The low dose already had launched the market two years earlier. Still, STADA, our business partner there, is doing quite well. We are, of course, with biosimilar to STELARA in U.S., again with Teva, doing well. We launched biosimilar to SIMPONI into Europe, among others, Lotus, Hulio, EYLEA, XGEVA. There, our marketing partner, Advanz, has already gained like 25% market share since we launched, and we are the only one on the market.
Overall, the base business as such is growing and will be growing into 2027.
Yeah. I guess one of the things that you started talking about maybe more this year is around diversifying the supply chain.
Yeah.
Right? You have talked about Lotte and Fujifilm.
Yeah
along with the Iceland facility that you have. When you think about the pipeline build-out from here, when do these suppliers start to come in? Have you identified each program, and how does this sort of work across the three different sources that you have?
Yeah. Yeah. So, we invested in Iceland in our facility north of $500 million already. So, the hub and the base is in Iceland. What we are seeing now is we have around 30 products in our pipeline, and we believe this is one of the broadest pipeline in the industry, which is in-house developed. None of our products are in-licensed or developed by someone else. It is all in-house. We are then at this inflection point where we are imminently going to launch three new products into U.S. We are gaining market share on market products. We are gaining market share with our, a strong share with our biosimilar to SIMPONI in Europe. We decided to broaden our supply chain, if you will.
We chose two companies which are based in U.S., so best-in-class access to the U.S. market and the quality having bigger manufacturing tanks than we have. We are doing 2,000 liter. We can scale up to 6,000 liter with those companies. We wanted to diversify a bit because we are getting so many launches and so many opportunities. We have filed a biosimilar to ENTYVIO, first to file there, and we have filed the high-dose EYLEA, and should be getting approvals next year. We wanted to make sure long term we had a very efficient supply chain with the option of lower, smaller batches up to 6,000 liter to make sure that in bigger volumes, we will be highly competitive to anyone in the market. We will be getting drug substance out of those two partners late next year.
Okay.
We will be seeing finished products coming out no later than first quarter 2028. All in all, super exciting. We are working with others also, but those two relationship are highly strategic long term we see.
Great. Yeah. And maybe just a couple of other sort of broad questions about the business. I think one of the things that I've heard Sandoz talk about is that they think that vertical integration is really a very big advantage.
Yeah.
And scale is a big advantage.
Yeah.
Because the way that Sandoz about it, I mean, is one of the players in the industry, I guess you can say, that they think that this is a very oligopolistic market.
Yeah.
That there is a huge scale advantage. So, if you have scale, you can drive the commercial business more attractively, right? I'm just curious to understand your perspectives of that, because obviously you're growing very rapidly-
Yeah
but you have a small base that you are growing from. When you think about the pipeline opportunities, like how much to sort of spread yourself thin
Yeah
what do you think about that?
Yeah, it is a good question. Overall, I just want to say, we are commercially very young company. I founded this 2013. Establishing a business like this and building out the full-fledged R&D, a very capable R&D, and in-house manufacturing takes eight to 10 years. As I mentioned, I am building out the portfolio. This has costed us over $2 billion. What we always believed in is that being end-to-end, when it comes to R&D, for instance, we have the flexibility. We have so far never failed any clinical. We have always been able to bring our best-in-class products forward, and that is a big benefit, especially in a world which is very dynamic. You asked about the portfolio. I can almost name most of them, if not all of them. HUMIRA was low dose.
We saw then AbbVie launching high dose into Europe, and we decided that day to stop and scrap $40 million we already invested in low dose, and we went straight to high dose.
Yeah.
We were the first to develop the high dose. We did the interchangeability study. We were the first coming with the interchangeability. We then saw, we are seeing a little bit similar dynamics in, of course, Eylea. Low dose out there. We heard about the high dose. We already formulated our product before Regeneron launched. I asked my team to come up with five, six option, how they would believe that Regeneron would do the high dose. And once they launched and we got the hands on the reference product, one of the formulation was spot on. We are then seeing, of course, ENTYVIO was vial, and five, six year later, closer to the patent expiry, they come with a prefilled syringe and auto-injector.
If you have an in-house development, you have all the flexibility not only to start the development, but to chase it in whichever direction it goes. In terms of production, I think it is a very complex production, drug substance especially, and having the understanding, deep understanding of the development and how to produce is super important. In my mind, if you look at the cost of producing biosimilars or biologics, most of the companies are buying from the same vendors, whether it is single use and disposable or stainless steel tanks. Most of us are building the same plants with the same condition and getting approvals around the world. Even though you place yourself in a lower cost labor area, usually you have to hire still people with a global experience, so the management will cost the same wherever you go.
I think the difference is, in many ways, is how well the product is developed. So, higher yield you can get without putting the biosimilarity at risk is the way to go. Of course, scale, whether you produce in big tanks or small tanks, basically is depending on the drug loads. But overall, what will be the main factor is the cell line and how you develop the product. We got approval now for a different process for biosimilar to HUMIRA. We originally developed our product in older version of our cell line. We have a very high-performing cell line today. We managed to double the output, so whenever we produce a batch, we now have a double output of drug substance.
We have like 6g/L in biosimilar to HUMIRA, but everything we are doing the last two years is well north of 10 g/L , up to 15.
Okay, great. Awesome. Thanks a lot for that. Now let's talk about, you have three approvals coming up.
Yeah.
A lot of excitement and some questions around that. This is sort of like a multi-layer process that
Yeah
needs to play out. Maybe if you can first talk about the FDA approval, then we'll talk about the launch, like all the different dynamics.
Yeah.
But yeah, just in terms of the approvability, I believe the FDA regulatory action expected in the very near term.
Yeah.
Just talk to us about your confidence in the ability to get these products approved.
We have a PDUFA date, December 4 for the three products, which are biosimilar to SIMPONI, low-dose EYLEA, and XGEVA. We have a strong conviction that this will be approved. We basically had three filings with FDA. One was doubling the output of our drug substance, and that was approved without prior inspection. Then changing the process of biosimilar to HUMIRA, the same, no inspection. We are pretty imminent now, as you said, less than three weeks to approval, so we are highly confident we will get approval. We are, of course, super excited about biosimilar to SIMPONI. We have been having that product now since last year in Europe. We are the only one. The market is a $3.5 billion total brand sales around the world, and we are doing well, Advanz our partner with 25% market share.
In U.S., there is another filer, Bio-Thera. They got injuncted by three patents which are not related to our processes. Janssen has asked for PI in our case. They have inserted only one patent. That patent is, first of all, we do not think really that they are using that process themself for SIMPONI. This is a different case, but we are doing. Our process is perfusion, so this patent simply do not apply to our process. So we feel very confident about getting approval, getting to market. We will be hopefully first, if not, then one of two. We are not aware of anyone coming anytime soon.
Yeah
This opportunity is really amazing.
Yeah
for us.
Yeah. If I can ask a couple of just follow-up questions on that. There is some sort of legal implications and how this will play out when the market starts to open. Kind of surprising to see the Bio-Thera PI, the way that it played out. Generally, when there is a preliminary injunction offered by one district
Yeah
court, the other district court might have to follow suit because this is a
Yeah
very recent legal precedent.
Yeah.
What do you think about that?
Yeah. I think the judge made it very clear when the legal from the other side mentioned that, I think, third time.
Yeah.
The judge said, "I have no interest in that. It's a different case.
Okay.
Bio-Thera process is totally different, and they inserted three different patents, totally different, which doesn't apply to us. So, all in all, which I want to also clarify, which I think is misunderstanding by some, whenever there's a PI request, parties need to put forward the bond, because if you ask for a PI, like in this case, Janssen preventing us to launch, you always have to put forward the bond. There is no speculation whether that's a win or lose situation. You have to put it forward. That's just customary. Then again, it's a fairly straightforward case, we believe. As I said, our production process is different from what this patent covers.
Yeah.
Secondly, which is kind of interesting, this patent that has no relevance to SIMPONI. I believe this is one of the patents which was acquired back in time, general patent, and does not cover our processes. That is kind of our position, and that is why we have been very outspoken that we are very confident.
The PI hearing was end of October, I believe?
The PI hearing was like two weeks ago.
When does it become abundantly clear to you that there is no outcome that would stop from PI perspective?
Yeah. I believe the ruling will come beginning of December, so it's fairly imminent.
Okay.
It should be around similar time if judge allows similar time as we get the approval.
Yeah. The judge is aware of the PDUFA dates that we have, and she said that she'll try to get it before that.
Yeah.
Right. Would that act as a trigger for them to make a decision with the PDUFA?
No, I think overall that would be convenient for us. And of course, Janssen will know then where they stand. But it would be very convenient for us to get that ruling before approval, definitely.
All right. Okay. Yeah. One of the things that I've been trying to sort of understand, and we'll get to the launch dynamic as well, but yeah, is that the milestone payments that you have
Yeah
right, are they more based on getting an approval, or does the product have to launch?
Yeah, I think overall, because our business concept is business to business, so we have reoccurring milestones going forward than in the past. How that work usually is that we get certain portion at the signing, and then we get the milestone as the R&D is progressing, typically around the clinical milestones, if you will. Then sometimes once we submit, and sometimes when we get approval. So, I would not say that every contract we make are the same. They follow the same kind of pathway, but they differ a bit based on how advanced we are. Sometimes when we sign, could be much more upfront than back-ended. If it is less advanced R&D, we might do more in the back. So, no, but overall, we have given out guidance for this year.
We mentioned that in our earnings call, and we still are confident with that, even though there might be milestone coming there or not.
Right. Okay. All right. Just in terms of the launch, like if we just stick to SIMPONI, what's your level of confidence that, like let's say the PI doesn't come
Yeah
but the process is still going on, right? What's your confidence level that Teva would actually launch the product?
No, I think we have amazing partner in Teva. They have shown they are able to convert. They are able to approach different channels. I think Teva has openly discussed that this one is an amazing opportunity for them. I believe that the stars align to go and make the most out of this. We have seen in Europe, in the short time we have been in the market, we have converted 25% of the market. We believe that we will be in a very strong position in U.S.
Yeah. Right. Awesome. When we think about the other products, right, like the low dose EYLEA and PROLIA/XGEVA, what is sort of the scale of the commercial opportunity for those two compared to SIMPONI?
Yeah.
I believe, like, those two do not have any sort of like a barrier to entry, right? Like, once you get the approval.
No, no. We did a settlement on the low dose.
Right.
The low dose is, as you know, Amgen was the first. They went at risk. There are four players coming in now with us, and one first quarter next year. Amgen came in with at least the WAC shows a very low discounts. We think the market is still there to hook up, and we think it is a good opportunity. On PROLIA/XGEVA, we have always said the brand price is very low, competition high, so we always have seen this as a much less of an opportunity, if you will.
So in terms of the pecking order, SIMPONI, low dose EYLEA, and PROLIA/XGEVA, is that fair?
Yeah, that's fair.
Okay. Yeah.
But in addition to that, of course, we were the first to file high dose, as I mentioned, and we think that's a great opportunity. There have been also discussion around the IP there. Those are all dosing patents. We are highly confident that in our case, we are running a validity case against some of the patents of Regeneron. There we believe that we will be successful, simply because it's partly because of obviousness and prior art, plus, we will also claim non-infringement in some of the cases. So, we are super excited about that product. As I said, we have submitted, we have filed, we have spent a few years and developed the device like the OcuClick, and that will be part of our offerings going forward. So, high dose should be approved in Europe next year.
We are also in a situation where ENTYVIO is already submitted in both U.S. and rest of the world.
That's also very super exciting program. Coming back to your question on selection, ENTYVIO was a small product when we decided to develop the product, smaller than we would typically go after. But we knew that Takeda was doing head-to-head study with HUMIRA, and we expected Takeda not to do that unless they were highly confident to get a good result. So we started to develop the product. The outcome was that ENTYVIO is showing much better efficacy when it comes to UC indication. Since then, the product has multiplied in sales.
Yeah.
That's the reason why we came first, and we managed to be first. Approval will be happening in Europe around March next year, and two months later in U.S. So it's not only the three products in play which are now on file, but we have two extremely exciting opportunities where we should be first to market with fairly big opportunities, if you will. I mean, ENTYVIO is $7.5 billion. We are seeing high dose more than 50% in Europe and 35%-36% of the market in U.S., and still converting.
Great. I'll just open up for anybody in the audience. I have a couple of other follow-ups as well, but just checking in if somebody has any questions. If not, then maybe just in terms of the SIMPONI market formation, if you can talk about. Yeah, it's interesting, maybe you might have this whole market to yourself now.
Yeah.
Right? If Bio-Thera is not going to be able to launch, what type of, like, if let's say, in that scenario, what type of pricing and market share could be up for grabs?
No, I mean, Bio-Thera launched alongside us in Europe.
In Europe, yeah.
They had to pull the product. We don't know, but we assume that they will be out at least until 2028. Being a formidable market, we want to be. Our philosophy is to sell a product where we are first, or at least in the first wave. Because if you want to really create any value for patients, and of course shareholder in the end of the day, I mean, you need to be first. Otherwise, you're not opening up the market. If you're launching into established market, usually the value is not there.
Yeah.
I think we might see first six months slower uptake. After that, we will see pretty strong uptake. We saw that with Lotus, Eylea, with Amgen.
Yes.
They were kind of first six months for a certain given reason. But overall, I mean, this looks like extremely lucrative opportunity.
Yeah, that's great. Then on ENTYVIO, CI said that probably somewhere in mid-year next year.
Yeah. So, end of first quarter March in Europe, mid-year U.S. We feel very strongly about our position there and the IP position. So again, I mean, it's both prior art, and we believe that our IP situation is super strong. So, it'll be exciting to follow next year.
Yeah. This is partnered with Teva, I believe?
Teva is in U.S. We have Advanz in Europe.
Right.
Advanz, again, is the one driving SIMPONI for us in Europe. Super good partner to work.
Great. I mean, is this true that there is a lot less number of competitors per biosimilar molecule now as opposed to four or five years ago? We have been hearing that from a few other industry participants as well.
Yeah.
But just curious to-
No, I think it is a very good question. I mean, my background, I have been seven global pharma companies, mostly been in generic biosimilars, of course, some branded businesses. And in the generic industry, you have 200 very active generic companies in biosimilars. If you look at end-to-end production development like we are doing, it is only a handful. Even though now the patient study is not required, the cost has come down. I mean, it was like HUMIRA with the interchangeability and the whole thing. I mean, I spent north of $300 million getting that product to market. It is totally different today. But still, you need to spend a significant amount of money. As I mentioned, our facility, which we have been building since 2016, is costing north of half a billion. Would cost much more today.
Each product in a pipeline, depending is it on oncology where you need potentially a real patient or not, could be between $50 million to $100 million. If you want to be a serious player, then you need to have a strong portfolio. So, it is not as easy to get into this industry investing close to a billion. By the way, it will take 10 years.
Yeah.
It is not everyone having that patience. I mean, we did that. As I mentioned, I think already twice, we invested $2 billion. 10 years is more than 10 years to pass when you are burning $2 billion or investing $2 billion, I can promise you.
Yeah.
A good way to look at it, Ash, is that six to seven of our next eight launches in the next two waves, they are all limited competition opportunities for us.
Yeah.
I mean, Róbert spoke about ENTYVIO, EYLEA high dose, and SIMPONI, and then the next wave after that will be Elrexfio, TREMFYA, Cimzia. Again, these are all limited competition opportunities for us. So, we are literally delivering that where we are going to be in a niche of our own, niche category of our own. So, yeah, that is a good proxy to look at.
Yeah.
Awesome.
All right, guys. With that, we are out of time. Thank you so much.
Yeah, thanks for having us. Bless you.
Thank you, Ash.
Thank you.
Bye, everyone.